Aquestive Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Daniel Barber
- Full Time Employees
- 147
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 30 Technology Drive Warren NJ United States of America 07059
- IPO Date
- Jul 25, 2018
- CIK
- 0001398733
- Website
- aquestive.com
- Similar Companies
- Business
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) develops and commercializes oral film-based pharmaceuticals utilizing its proprietary PharmFilm technology to deliver complex molecules as alternatives to invasive therapies; core products include Sympazan (clobazam oral soluble film) for Lennox-Gastaut syndrome seizures, Libervant (diazepam buccal soluble film) for seizure clusters, and manufacturing of licensed products such as Suboxone (buprenorphine/naloxone sublingual film) for opioid use disorder, KYNMOBI (apomorphine sublingual film) for Parkinson's disease off-periods, Azstarys for attention deficit hyperactivity disorder, Emylif, and Ondif; the pipeline features Anaphylm (epinephrine sublingual film) in late-stage development for anaphylaxis treatment pending FDA approval and AQST-108 (epinephrine topical gel) for dermatology conditions including alopecia areata, alongside the AdrenaVerse epinephrine prodrug platform. Founded in 2004 as MonoSol Rx and rebranded in 2017, the company is headquartered in Warren, New Jersey, and operates primarily in the United States with global licensing partnerships; it targets central nervous system disorders, severe allergies, and related conditions through collaborations with pharmaceutical firms like Assertio Holdings, Hypera Pharma, and Indivior, serving patients via innovative, needle-free delivery systems. Recent developments encompass a $75 million strategic funding agreement with RTW Investments in August 2025 to support Anaphylm commercialization through 2027 pending FDA approval, leadership expansion in November 2025 with Matthew Davis, M.D. as Chief Development Officer, Gary Slatko, M.D. as interim Chief Medical Officer, and Peter Boyd promoted to Chief People Officer to drive pipeline acceleration and launch readiness, FDA orphan drug exclusivity granted in December 2024 for Libervant in children ages 2-5, reaffirmation of Anaphylm NDA submission for Q1 2025 with pediatric trials underway, and positive pharmacokinetic data from October 2024 confirming consistent delivery regardless of placement.
Company News
Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $105,500.00 in Stock
Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Aquestive Therapeutics, Inc. $AQST Shares Sold by Squarepoint Ops LLC
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
8,069,373 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by BlackRock Inc.
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
AWM Investment Company Inc. Takes $1.98 Million Position in Aquestive Therapeutics, Inc. $AQST
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript
Aquestive Therapeutics Q2 Earnings Call Highlights
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript